Effect Of Allicin On Human Ovarian Cancer Cell A2780 And Its Mechanism

Objective:Explore the Allicin - joint cisplatin for ovarian cancer cell growth and A2780 - in effect of apoptosis mechanismsMethods:1 Methyl thiazolyl tetrazolium(MTT) method method detection of different concentrations of estrogen cisplatin combination in application of cell proliferation.2 Flow cytometric analysis of different concentrations of cisplatin combination in estrogen application in cell apoptosis.Results:1.Inverted microscope A2780 human ovarian cancer cell morphology(1) Control group: Ovarian cancer cells in good condition, cell stretch, cobblestone-like, over time, cells gradually increased and cell contacts close.(2) Allicin cisplatin in ovarian cancer cell group under the same time: 24h when the ovarian cancer can still form, a small amount of cytoplasm, vacuoles, cell gap between cells began to appear; 72h, the shrinkage is not clear dead cells, significantly smaller volume of space increases, some cells can be seen fragments of the nucleus, while the cytoplasm remained intact.(3) Allicinalone ovarian cancer and cisplatin after 24h after the interaction group: 24h in good condition when the ovarian cancer cell growth; 48h after the cell shape, small cytoplasmic vacuoles, intercellular start getting larger, part of the fragmentation of the nucleus can be seen dead cells.(4) Ovarian cancer with cisplatin alone a joint allicin 48h joint action group: 24h when no significant cell space and shrinkage. 72h, the medium can be seen with a large number of drug deaths of cell suspension, a small number of dead cells without signs of nuclear fragmentation, cell shrinkage significantly.2. Allicin combined with cisplatin on human ovarian cancer cell A2780 inhibited the proliferation effect.(1) Allicin-cisplatin in ovarian cancer cell group under the same time: the detection time significantly inhibited the proliferation of ovarian cancer, comared with the control group significantly (P<0.05). Concentration of estrogen liquid 50umol/L 72h when the interaction of cisplatin on ovarian cancer inhibition was most significant value-added, the two drugs have synergistic effects (q>1.15).(2) A2780 alone after 24h after ovarian cancer and cisplatin interaction group: 24h light to ovarian cancer cells to promote proliferation, but the difference was not statistically significant (P>0.05); 48h, 72h ovarian cancer when Cell proliferation was increased to varying degrees (P<0.05) were statistically significant. Concentration of estrogen liquid 100umol/L, 50umol/L, the two drugs have synergistic effects (q>1.15). Concentration of 50umol/L of estrogen interaction with cisplatin 72h inhibitory effect on ovarian cancer the most significant value.(3) Ovarian cancer with cisplatin alone a joint Allicin 48h joint action group: 24h, 48h ovarian carcinoma cell lines when more stable, compared with control group: 24h, 48h ovarian carcinoma cell lines when more stable, compared with control group (P<0.05) was statistically significant; 72h when the ovarian cancer cell proliferation in experimental group significantly increased (P<0.05) were statistically significant. Cisplatin alone by the joint concentration of 50umol/L common effect of estrogen on ovarian cancer cells to 72h, value-added impact of the most significant inhibition of the two drugs have a synergistic effect (q>1.15).3.Flow cytometric detection Allicin cisplatin combination of ovarian cancer cell A2780 apoptosis(1) Allicin-cisplatin in ovarian cancer cell group under the same time: 72h when the concentration of drugs for ovarian cancer cell apoptosis rates were 17.85%, 22.23%, 14.84%, 3.93%, and 3.65% compared to the control group, the difference was significant (p <0.05).(2) Allicin alone after 24h after ovrian cancer and cisplatin interaction group: 72h when the concentration of drugs for ovarian cancer cell apoptosis rates were 10.86%,11.98%, 7.19%, 3.92%, and control group relatively higher than 3.74%, the difference was statisticlly significant (p <0.05).(3)Ovarian cancer with cisplatin alone a joint Allicin 48h joint action group: 72h when the concentrations of drugs from the ovarian cancer cell lines were 23.47%, 26.89%, 23.97%, 17.82% 3.16% compared with the control group , the difference was statistically significant (p <0.05).Conclusion:1.Short simple application Allicin little effect on cell growth, suggesting that ovarian cancer patients before and given a short period of hormone replacement therapy does not cause disease progression.2.Cisplatin in combination with the Allicin inhibit ovarian cancer cell proliferation and apoptosis in ovarian cancer cells. Clinical applications can enhance the sensitivity to cisplatin, increased chemotherapy.3. Allicin cisplatin effect on people after the cells, and ovarian cancer cell proliferation, promote cell apoptosis than cisplatin, with Allicin combined application effect is better. Clinical application, give patients after treatment, cisplatin chemotherapy, the effect of hormone, both should be better.